Bicara Therapeutics Inc. ... (BCAX)
Bicara Therapeutics Common Stock Statistics
Share Statistics
Bicara Therapeutics Common Stock has 54.52M shares outstanding. The number of shares has increased by null% in one year.
Shares Outstanding | 54.52M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Institutions (%) | n/a |
Shares Floating | - |
Failed to Deliver (FTD) Shares | 969.08K |
FTD / Avg. Volume | 213.56% |
Short Selling Information
The latest short interest is 4.52M, so 8.31% of the outstanding shares have been sold short.
Short Interest | 4.52M |
Short % of Shares Out | 8.31% |
Short % of Float | 13.89% |
Short Ratio (days to cover) | 6.93 |
Valuation Ratios
The PE ratio is -43.05 and the forward PE ratio is -8.13. Bicara Therapeutics Common Stock's PEG ratio is 0.72.
PE Ratio | -43.05 |
Forward PE | -8.13 |
PS Ratio | 0 |
Forward PS | 3.2 |
PB Ratio | 5.95 |
P/FCF Ratio | -39.13 |
PEG Ratio | 0.72 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Bicara Therapeutics Common Stock.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 27.93, with a Debt / Equity ratio of 0.
Current Ratio | 27.93 |
Quick Ratio | 27.93 |
Debt / Equity | 0 |
Debt / EBITDA | -0.01 |
Debt / FCF | -0.01 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-1.24M |
Employee Count | 55 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | -187K |
Effective Tax Rate | 0.28% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is -1.41, so Bicara Therapeutics Common Stock's price volatility has been lower than the market average.
Beta | -1.41 |
52-Week Price Change | null% |
50-Day Moving Average | 13.06 |
200-Day Moving Average | null |
Relative Strength Index (RSI) | 40.87 |
Average Volume (20 Days) | 453.77K |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -82.39M |
Net Income | -68M |
EBITDA | -82.39M |
EBIT | n/a |
Earnings Per Share (EPS) | -0.4 |
Balance Sheet
The company has 489.71M in cash and 738K in debt, giving a net cash position of 488.97M.
Cash & Cash Equivalents | 489.71M |
Total Debt | 738K |
Net Cash | 488.97M |
Retained Earnings | -221.02M |
Total Assets | 524.17M |
Working Capital | 507.03M |
Cash Flow
In the last 12 months, operating cash flow was -74.75M and capital expenditures -71K, giving a free cash flow of -74.82M.
Operating Cash Flow | -74.75M |
Capital Expenditures | -71K |
Free Cash Flow | -74.82M |
FCF Per Share | -0.45 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
BCAX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for BCAX is $35, which is 195.9% higher than the current price. The consensus rating is "Buy".
Price Target | $35 |
Price Target Difference | 195.9% |
Analyst Consensus | Buy |
Analyst Count | 6 |
Scores
Altman Z-Score | 28.39 |
Piotroski F-Score | 2 |